Welcome to our dedicated page for Beta Bionics news (Ticker: BBNX), a resource for investors and traders seeking the latest updates and insights on Beta Bionics stock.
Beta Bionics reports developments for a commercial-stage medical device company focused on diabetes management for insulin-requiring people. Its core product, the iLet Bionic Pancreas, uses adaptive closed-loop algorithms and is an FDA-cleared insulin delivery device that autonomously determines insulin doses.
Company news commonly covers quarterly financial results and guidance, net sales through Durable Medical Equipment and Pharmacy Benefit Plan channels, new patient starts, product software such as Bionic Insights within Bionic Reports, and diabetes-technology development programs including the Mint patch pump and bihormonal system.
Beta Bionics (Nasdaq: BBNX) reported third quarter 2025 results and raised full‑year guidance. Q3 net sales $27.3M (+63% YoY) with DME sales $21.0M (+45%) and PBP sales $6.2M (+178%). Gross margin was 55.5% (up 212 bps). Installed customer base reached 29,419 users (+162% YoY) with 5,334 new patient starts (+68%), ~70% from MDI. Loss from operations was $17.0M; net loss $14.2M; adjusted EBITDA was negative $12.2M. Cash and investments totaled $274.0M as of Sept 30, 2025. Management completed a glucagon PK/PD trial, expects a New Zealand feasibility trial in Q4 2025, and received Special 510(k) updates for iLet on Sept 29, 2025. Full‑year 2025 revenue guidance raised to greater than $96.5M.
Beta Bionics (Nasdaq: BBNX) will release its third quarter 2025 financial results after market close on Tuesday, October 28, 2025. Management will host a conference call and concurrent webcast the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The webcast link will be posted and archived in the company’s Investors & Events section at https://investors.betabionics.com. Phone access requires registration for dial-in details and a personal PIN via https://register-conf.media-server.com/register/BI0b27b735377640268ec22270324ddd73.
Beta Bionics (Nasdaq: BBNX), a leader in advanced diabetes management solutions, has announced its participation in three major healthcare investor conferences in September 2025. The company will present at the Wells Fargo Healthcare Conference (September 4), Morgan Stanley Global Healthcare Conference (September 8), and Baird Global Healthcare Conference (September 10).
Live webcasts will be available for the Wells Fargo and Morgan Stanley presentations through the company's investor relations website, where recordings will also be archived for future viewing.
Beta Bionics (Nasdaq: BBNX) reported strong Q2 2025 financial results, with net sales reaching $23.2 million, up 54% year-over-year. The company's installed customer base grew 200% to 24,085 users, with 4,934 new patient starts in Q2. The company achieved significant growth in both DME and PBP channels, with PBP channel sales surging 498% to $4.6 million.
Key operational metrics showed improvement with gross margin reaching 53.8%. Despite growth, the company reported a net loss of $16.9 million. Beta Bionics raised its full-year 2025 guidance, projecting revenue of $88-93 million, up from previous guidance of $82-87 million.
Strategic highlights include securing formulary agreements with major PBMs and completing dosing in the glucagon PK-PD bridging trial for their bihormonal configuration development.
Beta Bionics (Nasdaq: BBNX), a leader in advanced diabetes management solutions, will release its Q2 2025 financial results on Tuesday, July 29, 2025, after market close. The company will host a conference call and webcast at 4:30 PM ET on the same day.
Investors can access the webcast through the company's investor relations website under the "Events & Presentations" section, where it will also be archived for future viewing. For those joining by phone, registration is available through a dedicated link that will provide dial-in details and a personal pin.
[]Beta Bionics (BBNX), a company focused on diabetes management solutions, has announced its participation in the upcoming Bank of America Securities Health Care Conference. The presentation is scheduled for Tuesday, May 13, 2025, at 12:35 PM ET (9:35 AM PT) in Las Vegas. Interested parties can access the live audio webcast through the company's investor relations website under the "Events & Presentations" section at investors.betabionics.com. The presentation recording will be archived on the website for future viewing.
Beta Bionics (Nasdaq: BBNX), a leader in advanced diabetes management solutions, has scheduled the release of its first quarter 2025 financial results for Tuesday, May 6, 2025, after market close.
The company will host a conference call and simultaneous webcast at 4:30 PM Eastern Time (1:30 PM Pacific Time) on the same day. Investors can access the live call by dialing (888) 596-4144 with passcode 8363701. The webcast will be available in the Investors—Events & Presentations section of the company's website and will be archived for future viewing.
Beta Bionics (Nasdaq: BBNX) has announced an upcoming investor event scheduled for June 22, 2025, in Chicago, coinciding with the 85th Scientific Sessions of the American Diabetes Association. The event will run from 7:00 AM to 8:30 AM Central Time.
The presentation will feature:
- Commercial and financial performance updates
- Demonstration of new patch pump development
- Review of adaptive closed-loop algorithm
- Presentation of new real-world clinical data
The event will be accessible via live webcast through the company's investor relations website. In-person attendance requires registration through Beta Bionics' IR representative. A replay of the webcast and presentation materials will be available on the company website after the event.